Drugs / Tetanus
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Hexyon | — | 2013-02-22 | europa.eu ↗ |
| Approved | EU (EMA) | Infanrix HepB | — | 1997-07-30 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01611298 | Mar 2008 → Nov 2012 | Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +1 | Robert Krance | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01611298 ↗ |
| Modality | Vaccine | “tetanus vaccine” NCT01611298 ↗ |
| Route | Intramuscular | “0.5mL intramuscularly into deltoid or medial lateral thigh” NCT01611298 ↗ |